Home›Trial›NCT06117774
🔬NCT06117774Phase 3RECRUITING

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

Study Summary

The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on blinded independent central review (BCIR) per response evaluation criteria in solid tumors v1.1 (RECIST 1.1) and on prolonging overall survival (OS).

Conditions
Limited Stage Small Cell Lung CancerSmall Cell Lung Cancer
Interventions / Drugs
TarlatamabPlacebo
View on ClinicalTrials.gov ↗
Sponsor
AMGN
Amgen Inc
Biologics
F33/100
Study Details
Enrollment400 participants
Primary Completion—
Lead SponsorAmgen
Data Retrieved2026-04-13 18:29:34.158254+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.